Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

Schmidt & Clark, LLP: FDA Reports Show Abbott Labs Subsidiary Failed to Disclose Parasite Eye Infections Tied to Contact Lens Solution

Mon. June 22, 2009; Posted: 01:06 PM
Stocks RSS
WASHINGTON, June 22, 2009 /PRNewswire-FirstCall via COMTEX/ -- ABT | Quote | Chart | News | PowerRating -- The Washington, D.C.-based law firm of Schmidt & Clark, LLP, is announcing the results of an inspection conducted by the U.S. Food and Drug Administration where investigators determined that a subsidiary of Abbott Park, Ill.-based Abbott Laboratories Inc. (NYSE: ABT | Quote | Chart | News | PowerRating) failed to disclose multiple reports of a serious parasitic eye infection for more than a year.

In an Associated Press story reported June 20, 2009, Schmidt & Clark Managing Partner Michael Schmidt says the documents reveal the link between Acanthamoeba Keratitis and a popular contact lens solution sold by Irvine, Calif.-based Abbott Medical Optics ("AMO"), an Abbott Labs subsidiary.

"It confirms our suspicion that AMO knew, or should have known, that there was a significant increase in Acanthamoeba Keratitis cases associated with Complete MoisturePlus," Mr. Schmidt says in the article.

According to the report obtained under the Freedom of Information Act, inspectors from the FDA discovered that AMO failed to disclose at least nine reported cases of the sight-threatening eye infection Acanthamoeba Keratitis among users of the company's Complete MoisturePlus contact lens solution.

According to the FDA report, AMO began receiving complaints of serious corneal infections in February 2006, but those reports were not disclosed until an FDA inspection in late May and early June 2007. The Centers for Disease Control launched its own investigation after receiving increasing reports of the rare infection.

AMO finally recalled Complete MoisturePlus in May 2007 after the Centers for Disease Control released data showing that users of the product were seven times more likely to be infected with Acanthamoeba Keratitis than those who never used Complete MoisturePlus. The FDA subsequently categorized the withdrawal as a Class I recall, a status reserved for situations where there is a reasonable probability that the recalled product will cause serious health problems or deaths.

Currently, more than 150 former users of Complete MoisturePlus are pursuing injury lawsuits against AMO in Orange County Superior Court, including some victims who have lost sight or suffered eye removal. An undetermined number of people suffered vision loss and eye injuries as result of their use of Complete MoisturePlus. To learn more about Acanthamoeba Keratitis or the Complete MoisturePlus Recall please visit the Schmidt & Clark website at www.schmidtandclark.com.

For more information, please contact Bruce Vincent at 800-559-4534 or bruce@androvett.com.

SOURCE Schmidt & Clark, LLP

http://www.schmidtandclark.com/
For full details on Abbott Laboratories (ABT) click here. Abbott Laboratories (ABT) has Short Term PowerRatings of 5. Details on Abbott Laboratories (ABT) Short Term PowerRatings is available at This Link.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [ABT]
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.